Research Studies

Sign up by: March 31, 2023

HANDDS-ONT takes place in the participant's home and community. We are seeking people living with a neurodegenerative disease or post-stroke, along with healthy controls. Our objectives: to understand how these diseases affect different people; discover ways to detect diseases earlier; explore ways to help people manage health related behaviours. Participant data is collected through small sensors worn on the wrist, ankle and chest for 7-10 days, along with assessment questionnaires and blood samples. Combining all this data will enable an understanding of daily challenges in aging while living with or without a neurodegenerative condition. Participants receive a personalized health and activity report from the period the sensors are worn. This information may help participants to better understand and manage some aspects of their health and it can be shared with their circle of care. Feedback on this report is requested as part of the study. For more see www.ondri.ca/handds

Key Details

Study sponsor: Funding for HANDDS-ONT is provided by the Ontario Brain Institute (OBI). OBI is partially funded by the government of Ontario.

Location: Required in-person participation - Blood sample is provided in community Lifelabs location. Optional internet participation. Optional phone participation.

How Often: Biweekly

Compensation: None

Contact: HANDDS-ONT Project coordinator, Ontario Neurodegenerative Disease Research Initiative

[email protected]

437-882-8335

Sign up by: 31 December 2022 The Dementia Resources for Eating, Activity, and Meaningful Inclusion (DREAM) project aims to improve the quantity, quality, and variety of community-based physical activity, healthy eating, and wellness opportunities for people living with dementia. To do so, our team created a website with resources for community service providers, people living with dementia, and care partners to support people living with dementia to be physically active, eat healthy, and live well. Participation in this study would include reviewing our website, utilizing the resources of interest, and answering some questions about your experience, physical activity, eating habits, and feelings of inclusion in your community. Key Details Study Sponsor: This study is funding by the Public Health Agency of Canada, and includes the following research and community partners: University of Waterloo, University of Northern British Columbia, Alzheimer Society of Ontario, Alzheimer Society of British Columbia, Alzheimer Society of Waterloo-Wellington, YMCA's of Cambridge, Kitchener-Waterloo, Active Health Solutions, City of Kitchener, BC Ministry of Health, Caredove, Canadian Nutrition Society, Canadian Society for Exercise Physiology, University Health Network, Ontario Brain Institute, Waterloo Region Dementia Advocacy Group, Ontario Community Support Association, Ontario Kinesiology Association, Research Institute for Aging, Dementia Advocacy Canada, Patient Voices Network, Dieticians of Canada, Roots to Harvest, Costi, and Community Support Connections. Location: Phone (Required)+ Internet (Optional) How Often: Biweekly Compensation: $100 upon completion of last survey/interview Contact: DREAM Research Team [email protected]

Sign up by: 30 April 2025
This is a 5-year study which aims to evaluate and characterize frontotemporal lobar degeneration (FTLD) patients and asymptomatic individuals belonging to family with a strong history of an FTLD syndrome and their caregivers. This study seeks to learn more about how FTLD syndromes progress over time and to develop new tools that can aid with diagnosis, treatment and monitoring of FTLD.

Key Details
Study Sponsor: Funding: NIH International Study on FTD
Location: In-person (Required at Toronto Western Hospital)
How Often: Yearly
Compensation: Yes (Participants will be compensated for their travel, time and parking.)

Contact: Daniela Mora-Fisher, Clinical Research Coordinator
[email protected]
(416) 603-5914

Sign up by: 01 January 2023

The drug being studied is called JNJ-63733657. All reference to the words "study drug" can mean JNJ-63733657 or non-active placebo. A placebo is an inactive substance used as a control in a clinical study, to determine whether and how well the investigational drug works. In this study, the placebo will be a liquid that looks exactly like the investigational drug and is given in the same way but that contains no active drug. The purpose of this study is to see if JNJ-63733657 is safe and useful for treating participants with Early Alzheimer's disease defined as prodromal and mild dementia due to Alzheimer's disease. JNJ-63733657 is a tau monoclonal antibody that is designed to bind to tau in the brain. Tau is a protein that builds up in the brain and may cause memory loss. This study will determine if this antibody may prevent the tau from spreading in the brain and slow cognitive decline.

Key Details
Study Sponsor: Study Sponsor: Janssen Research & Development, LLC
Location: In-person (Required at Toronto Western Hospital)
How Often: Monthly
Compensation: Yes ($50 per visit)

Contact: Behnaz Ghazanfari or Amy Obssi, Memory Clinic Research Coordinator
[email protected]
(416) 603-5910

Sign up by: 31 December 2022

The purpose of the current study is to see whether the study drug, GV-971, improves AD symptoms, and how safe it is. The study will also look at what the body does to the study drug, such as how the body breaks down and uses the study drug and how it is removed from the body. This is known as pharmacokinetics. The study drug is currently approved for use in China for the treatment of mild to moderate AD. The study drug is made from a seaweed called brown algae. A specific sugar contained within the seaweed suppresses certain bacteria contained in the gut, which can cause harm to the brain, leading to AD. Approximately 2046 participants in around 200 study centers around the world will take part in this study.

Key Details
Study Sponsor: Sponsor of study is Shanghai Green Valley Pharmaceutical Co., Ltd.
Location: In-person (Required at Toronto Western Hospital)
How Often: Monthly
Compensation: Yes ($50 per visit)

Contact: Behnaz Ghazanfari, Memory Clinic Research Coordinator
[email protected]
416-603-5800 Ext.5910

Sign up by: 01 September 2025

Caregiving for people with dementia has become an issue of international importance. The focus of research in caregiver burden and distress in neurodegenerative disease has been on the patients' cognitive deficits and neuropsychiatric symptoms. Social cognition comprises many psychological processes that allows individuals to partake in social situations by enabling them to perceive and recognize the thoughts, emotions, and behaviours of others. There is growing awareness of social cognitive deficits occurring in the different neurodegenerative diseases. People with dementia may display increasing difficulties in understanding social cues or recognizing emotions and caregivers are generally unaware of these deficits. There is growing evidence that changes in emotion recognition can impact caregiver mood and be associated with caregiver burden.

This is a pilot project to assess the feasibility of educating dementia caregivers on emotion recognition deficits and decreased empathy in patients with dementia and the impact of education on caregiver burden, mood and quality of life. Seventy-five dementia caregiver-patient pairs will be recruited for this cross-sectional study. Caregivers' ability to detect emotion recognition deficits and empathy impairment in the patient will be assessed. Caregivers will be given a questionnaire to evaluate their knowledge of emotion recognition deficits and empathy impairment in the patient. Caregiver burden, mood, and quality of life will be assessed. The caregivers will then be given educational material on emotion recognition deficits and empathy impairment in dementia and then be asked to evaluate the information they have received. After 1 month, caregivers will be contacted to assess whether the information they received changed their understanding of emotion recognition deficits and empathy impairment and if it had an impact on caregiver burden, mood and quality of life.

Key Details
Study Sponsor: Toronto Western and General Hospitals
Location: In-person (Optional at Toronto Western Hospital) + Phone (Optional)
How Often: Yearly
Compensation: No

Contact: Daniela Mora-Fisher, Clinical Research Coordinator
[email protected]
416-603-5914

Sign up by: 01 September 2025

This study follows people with progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) for up to 2 years and compares their brain changes with healthy volunteers of the same age. Researchers hope to learn more about how patients with PSP and CBD progress over time and which measures are best for tracking change and predicting progression. Various measures including brain imaging, cerebrospinal fluid analysis, eye tracking, blood markers and neuropsychological testing will be measured.

Key Details
Study Sponsor: Mayo Clinic NIH
Location: In-person (Required at Toronto Western Hospital)
How Often: A few times a year + Yearly
Compensation: Yes (Participants will be compensated for their time and expenses)

Contact: Daniela Mora-Fisher, Clinical Research Coordinator
[email protected]
416-603-5914

Sign up by: 25 November 2023

The main goal of the S-citAD study is to assess the safety and efficacy of escitalopram (a drug) in combination with psychosocial intervention as a treatment for agitation in patients with Alzheimer's disease. It will also look at the predictors of relapse and response duration, in patients with Alzheimer's disease with agitation who improve with psychosocial intervention, as well as those who do not improve with psychosocial intervention. This 24-week trial (12 weeks treatment; 12 weeks follow-up) enrolls participants from real world settings such as outpatient and assisted living facilities.

Key Details
Study Sponsor: This study is funded by the National Institute on Aging (NIA)/ Johns Hopkins University.

Currently Enrolling: Individuals living in Whitby and the surrounding areas including the greater Toronto area

Location: In-person (Required at Ontario Shores Centre for Mental Health Sciences*) + Phone (Optional) + Internet (Optional)

*The majority of the visits during this study will be completed via phone or video calls. However, participants will be required to come to Ontario Shores Centre for Mental Health Sciences for 2 or 6 visits during the 15-week treatment period.

How Often: Monthly
Compensation: Yes (Participants will receive payment of $25 per visit*)

*This applies to the first two visits, as well as Week 3, Week 6, Week 9 and Week 12. For in-person visits, participants will receive payment at the end of the visit. For telephone/video contacts, participants will be emailed an electronic gift card/cheque by regular mail (Canada Post).

Contact: Elaina Niciforos, Lead Study Co-ordinator

[email protected]

905-430-4055 Ext. 6139

905-430-4055 Ext. 6423